Open Orphan: Flu vaccine data showcased in peer reviewed article – Proactive Investors April 17, 2020 – Posted in: Open Orphan (ORPH)

by Ian Lyall.  FLU-v has been developed by Imutex, 49%-owned by Open Orphan unit hVIVO The results of a successful phase IIb trial of a potential flu vaccine being developed by an Open Orphan PLC  (LON:ORPH) joint-venture have been written up in a peer-reviewed article carried by a scientific journal. The data from FLU-v 004 challenge study underlined its ability to reduce mild-to-moderate symptoms of the illness. FLU-v has been developed by Imutex, 49%-owned by…

Continue reading